Status:

RECRUITING

Immunoinflammatory Regulation of Esketamine in Septic Patients

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions:

Esketamine

Sepsis

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

Studies have shown that excessive systemic inflammatory response and concomitant immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is very important to reduce ...

Eligibility Criteria

Inclusion

  • 18 years old ≤ age ≤60 years old;
  • SOFA score ≥2;
  • Mechanical ventilation should be required for at least 24 hours when included in the study;
  • Informed consent is obtained.

Exclusion

  • Age \< 18 years old or ≥ 60 years old;
  • Previous solid organ or bone marrow transplantation;
  • Autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), or hematologic malignancies (leukemia and lymphoma, etc.);
  • Received radiotherapy or chemotherapy within the past 30 days, or received immunosuppressant drugs (tripterygium wilfordii, mycophenolate mofetil, cyclophosphamide, FK506, etc.), or continuous treatment with prednisolone more than 10 mg/day (or equivalent doses of the other hormones);
  • Unstable angina pectoris or myocardial infarction in the past six months;
  • Acute brain injury (traumatic brain injury, subarachnoid hemorrhage, acute ischemic stroke, acute intracranial hemorrhage, acute intracranial infection, etc.);
  • Poorly controlled hypertension and congestive heart failure;
  • Increased intraocular or intracranial pressure;
  • Chronic kidney disease, received continuous renal replacement therapy in the past 30 days, or acute renal failure requiring CRRT;
  • Severe chronic liver disease (Child-Pugh class B or C);
  • Alcohol dependence, mental illness or severe cognitive impairment;
  • Pregnancy or lactation;
  • Informed consent is not obtained.

Key Trial Info

Start Date :

July 28 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 30 2026

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04843982

Start Date

July 28 2021

End Date

October 30 2026

Last Update

July 18 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China, 430022

2

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China, 430022

Immunoinflammatory Regulation of Esketamine in Septic Patients | DecenTrialz